Italy Porcine Vaccines Market

ID: MRFR/Pharma/48723-HCR 200 Pages Vikita Thakur Last Updated: September 17, 2026
Italy Porcine Vaccines Market Research Report By Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD), Others) and By End-user (Veterinary Hospitals, Hog Production Farm) - Growth & Industry Forecast 2025 To 2035
Italy Porcine Vaccines Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.41%
2024 Market Size$ 67.2 Million
2025 Market Size$ 70.84 Million
2035 Market Size$ 120 Million
Key Players
Zoetis
Merck Animal Health
Boehringer Ingelheim
Elanco Animal Health
Ceva Santé Animale
Virbac
Opportunities
  • Emerging Infectious Diseases
  • Expansion of Veterinary Services
  • Government Initiatives and Funding
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Type (USD Million)
      1. 4.1.1 Inactivated vaccines
      2. 4.1.2 Live attenuated vaccines
      3. 4.1.3 Toxoid vaccines
      4. 4.1.4 Recombinant vaccines
      5. 4.1.5 Conjugate vaccines
      6. 4.1.6 DNA vaccines
    2. 4.2 Chemicals and Materials, BY Disease Indication (USD Million)
      1. 4.2.1 PED (Porcine Epidemic Diarrhea)
      2. 4.2.2 PRRS (Porcine Reproductive & Respiratory Syndrome)
      3. 4.2.3 Swine influenza
      4. 4.2.4 Aujeszky's disease (AD)
      5. 4.2.5 Porcine Circovirus Associated Disease (PCVAD)
      6. 4.2.6 Others
    3. 4.3 Chemicals and Materials, BY End-user (USD Million)
      1. 4.3.1 Veterinary Hospitals
      2. 4.3.2 Hog Production Farm
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Zoetis (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Merck Animal Health (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Boehringer Ingelheim (DE)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Elanco Animal Health (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Ceva Santé Animale (FR)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Virbac (FR)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Heska Corporation (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Vetoquinol (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 ITALY MARKET ANALYSIS BY TYPE
    3. 6.3 ITALY MARKET ANALYSIS BY DISEASE INDICATION
    4. 6.4 ITALY MARKET ANALYSIS BY END-USER
    5. 6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    8. 6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    11. 6.11 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
    12. 6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
    13. 6.13 CHEMICALS AND MATERIALS, BY DISEASE INDICATION, 2024 (% SHARE)
    14. 6.14 CHEMICALS AND MATERIALS, BY DISEASE INDICATION, 2024 TO 2035 (USD Million)
    15. 6.15 CHEMICALS AND MATERIALS, BY END-USER, 2024 (% SHARE)
    16. 6.16 CHEMICALS AND MATERIALS, BY END-USER, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DISEASE INDICATION, 2025-2035 (USD Million)
      3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Italy Porcine Vaccines Market Segmentation

Italy Porcine Vaccines Market By Type (USD Million, 2025-2035)

  • Inactivated vaccines
  • Live attenuated vaccines
  • Toxoid vaccines
  • Recombinant vaccines
  • Conjugate vaccines
  • DNA vaccines

Italy Porcine Vaccines Market By Disease Indication (USD Million, 2025-2035)

  • PED (Porcine Epidemic Diarrhea)
  • PRRS (Porcine Reproductive & Respiratory Syndrome)
  • Swine influenza
  • Aujeszky's disease (AD)
  • Porcine Circovirus Associated Disease (PCVAD)
  • Others

Italy Porcine Vaccines Market By End-user (USD Million, 2025-2035)

  • Veterinary Hospitals
  • Hog Production Farm
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.